• At the 2026 ASCO meeting, Immatics reported extended Phase 1 and 1b data showing deep, durable responses and manageable safety for its PRAME-targeted cell therapies and IMA401 bispecific across multiple hard-to-treat solid tumors, reinforcing progress of its lead programs in advanced melanoma, gynecologic cancers, synovial sarcoma, and head and neck cancer.
• A distinctive takeaway is how Immatics is building an integrated PRAME franchise, spanning TCR T-cell therapies and bispecifics, aimed at more than 50 cancer types and already moving one asset into a Phase 3 trial with parallel expansion cohorts.
• Next, we’ll examine how the breadth of Immatics’ PRAME-focused pipeline at ASCO shapes the company’s longer-term investment narrative.

Find 44 companies with promising cash flow potential yet trading below their fair value.

What Is Immatics' Investment Narrative?

For Immatics, the core investment belief now rests on its ability to turn an increasingly coherent PRAME and MAGEA4/8 franchise into real, late‑stage assets. The new ASCO data strengthen that story: anzu‑cel’s extended Phase 1b melanoma results backstop the ongoing SUPRAME Phase 3, IMA203CD8 broadens the addressable tumor set into gynecologic cancers and sarcoma, and IMA401/402 bispecific data hint at combination potential in lung and head and neck cancer. Together, this makes clinical execution around SUPRAME, setting an RP2D for IMA203CD8, and advancing the IMA401/402 combo the near‑term catalysts that matter most. At the same time, Immatics is still loss‑making with a rich sales multiple and has relied on equity raises, so any stumble in data, timelines or financing could weigh heavily, despite the supportive news flow.

However, the company’s heavy cash burn and recent equity raises are risks investors should be aware of. In light of our recent valuation report, it seems possible that Immatics is trading beyond its estimated value.

Exploring Other Perspectives

Three Simply Wall St Community fair values, spanning roughly US$7 to US$19 per share, show just how far apart individual expectations sit. Set that against the recent ASCO data, which sharpen near term trial milestones and financing needs, and you can see why it pays to compare multiple viewpoints before forming your own view on Immatics’ prospects.

Explore 3 other fair value estimates on Immatics - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Immatics research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Immatics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immatics' overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.